Our inquiry requests information on the factors driving these shortages and scrutinizes the practices of opaque drug middlemen.
They sometimes offered below-market prices to get big contracts, a strategy that had eroded stability in the industry, especially among makers of sterile injectable products often used in surgical and cancer care.
#federal-trade-commission #department-of-health-and-human-services #generic-drug-shortages #middlemen #supply-chain
[
add
]
[
|
|
...
]